Acadia Pharma (ACAD) Misses Q1 EPS by 10c; Offers FY22 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. CART

Go back to Acadia Pharma (ACAD) Misses Q1 EPS by 10c; Offers FY22 Guidance

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

May 4, 2022 4:05 PM EDT

- 1Q22 net sales of $115.5 million, an 8% increase over 1Q21

- Reiterating FY22 net sales guidance of $510 to $560 million

- FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022.

NUPLAZID continued to deliver year over year growth in the first quarter of 2022, said Steve Davis, Chief Executive Officer. In the near... More